MedTrace Logo

A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and Persistently Normal Alanine Transaminase (ALT) Levels

NCT02726022 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 114

Last updated 2016-08-15

Study results available
· View outcomes & findings →

Summary

Participants with Chronic Hepatitis C (CHC) and normal ALT, who have been under treatment with peginterferon alfa-2a and ribavirin for at least 4 weeks, will be enrolled into this non-interventional, open-label study. The primary aim is to evaluate quality of life according to the 36-Item Short-Form Health Survey (SF-36) questionnaire, modified for the Greek population.

Conditions

  • Hepatitis C, Chronic

Interventions

DRUG

Peginterferon alfa-2a

As per treating physician discretion and according to summary of product characteristics.

DRUG

Ribavirin

As per treating physician discretion and according to summary of product characteristics.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02726022 on ClinicalTrials.gov